In October last year, Sage Therapeutics announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae (zuranolone) in postpartum depression. The company ...

Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

The Company Remains Focused on the Goal of Establishing ZURZUVAE as the Standard of Care for Women with Postpartum Depression Sage Therapeutics, Inc. (Nasdaq: SAGE) (“Sage” or “the Company ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...

Sage Therapeutics and Biogen have a collaboration deal for the commercialization of Zurzuvae, which was approved for treating postpartum depression in August 2023. The drug was commercially ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

for the treatment of postpartum depression. Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

Sage Therapeutics and Biogen have a collaboration deal for the commercialization of Zurzuvae, which was approved for treating postpartum depression (PPD) in August 2023. The drug was commercially ...